Atopic dermatitis, the most common form of eczema, causes itchy, inflamed skin that can flare unpredictably. It affects about one in ten people, often starting in childhood. Treatment has expanded beyond topical steroids to include newer drugs that target specific parts of the immune system causing inflammation.
What's actually going on in research
Trials are testing JAK inhibitors in pill and cream forms, monoclonal antibodies that block different inflammation signals, and treatments for the intense itch that disrupts sleep and daily life. Researchers are also studying the skin barrier defects that let allergens in and testing microbiome-based therapies that may restore healthy skin bacteria.
JAK inhibitors
Pills like upadacitinib and abrocitinib can clear severe atopic dermatitis within weeks by blocking inflammation signals inside immune cells. New topical JAK inhibitors, including ruxolitinib cream, offer targeted relief without systemic exposure.
Biologics targeting IL-13
Following dupilumab's success blocking IL-4 and IL-13, newer antibodies targeting IL-13 alone are showing promise. These injections may offer similar skin clearing with potentially fewer side effects.
Itch-specific treatments
Researchers are testing drugs that target nerve pathways responsible for itch rather than just inflammation. This could help the many people whose itch doesn't fully resolve with current treatments.
What to know before you search
Eligibility typically depends on disease severity measured by body surface area affected, itch intensity scores, whether topical steroids have failed, and age.
What types of trials are currently open
- JAK inhibitor trials — Testing oral pills or topical creams that block inflammation signals. These often show results within weeks and may work for people who haven't responded to other treatments.
- Biologic trials — Testing injections of antibodies that block specific proteins driving inflammation, often given every two to four weeks.
- Barrier repair trials — Testing creams and treatments that strengthen the skin's protective barrier, which is defective in atopic dermatitis.
- Microbiome trials — Testing probiotics, prebiotics, or bacteria-based therapies to restore healthy skin microbes and reduce Staph aureus colonization.
- Pediatric trials — Testing treatments specifically in children with atopic dermatitis, since the condition often starts before age five and may respond differently than in adults.
Recently added Atopic Dermatitis trials
Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares
This study will collect skin measurements from people with atopic dermatitis (AD) using the investigational Nevisense Go device. Participants aged 12 to 89 years with a history of AD flares will use the device at home for about 90 days. Participants will complete device measurements, electronic diary entries, and up to five in-person study visits. The study is based on the idea that changes in skin barrier function may occur before an AD flare becomes visible or symptoms begin. Information collected during the study, including device measurements, diary entries, and investigator assessments, will be used to evaluate whether these changes may help estimate the likelihood of an AD flare before visible signs or symptoms occur.
A First-in-human Study to Investigate Single Doses of DCY636 in Healthy Volunteers and Multiple Doses in Participants With Moderate to Severe Atopic Dermatitis
The purpose of this first-in-human (FIH) study is to assess the safety and tolerability, pharmacokinetics (PK), immunogenicity (IG) and pharmacodynamics (PD) of DCY636. The results are intended to support the further clinical development of DCY636 in future studies.
Find Atopic Dermatitis trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.